Navigation Links
Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands

MORRISTOWN, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that G. Frederick Wilkinson has joined the Company as Executive Vice President, Global Brands. In this newly expanded position Mr. Wilkinson will be responsible for all aspects of the Company's global brand pharmaceutical business, including brand product development, global sales and marketing and coordinating brand product business development activities. In addition, Mr. Wilkinson will oversee Watson's biologic development efforts. Mr. Wilkinson will report directly to Paul Bisaro, President and Chief Executive Officer.

"Fred returns to Watson with an extraordinary record of accomplishments having built a successful brand products business at Duramed Pharmaceuticals, the brand business of Barr Pharmaceuticals, particularly in the area of women's healthcare," said Paul Bisaro, Watson CEO. "We will look to Fred to further strengthen our US brand business, which includes a strong product portfolio supported by the recent launches of RAPAFLO(R) and Gelnique(R)."

"Fred's global experience will also be invaluable as we seek to maximize opportunities for our brand portfolio in new markets that will result from the successful acquisition of Arrow Group, which is expected to close this fall," Bisaro added. "Finally, Fred's experience in biologics, including expansion of Barr's biopharmaceutical production capabilities, development of a pipeline of early stage projects, and his work to shepherd Barr's initial biologics vaccine product through the FDA clinical development process, will enable him to effectively guide our efforts in becoming a leader in the generic biologics area."

Most recently, Mr. Wilkinson served as President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., the proprietary products subsidiary of Barr Pharmaceuticals, Inc. He joined Duramed in 2006 and had responsibility for the Company's successful expansion of Duramed's female healthcare product franchise and pipeline, and for managing Barr's biologics initiatives. Prior to joining Duramed Pharmaceuticals, Mr. Wilkinson served as President and Chief Executive Officer of Columbia Laboratories since 2001. From 1996 to 2001, Mr. Wilkinson was Senior Vice President and Chief Operating Officer of Watson Pharmaceuticals. Prior to joining Watson, he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions of increasing responsibility.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).

For press releases and other company information, visit the Watson Web site at

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Florida Hospital Tampa is the ... of obesity in the state of Florida. , vBloc® Therapy is a vagal blocking therapy, ... 18 years with a body mass index (BMI) of at least 40 to 45 kg, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... is everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ ... next product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology: